Related Experiment Videos
[The therapy of Raynaud's phenomenon]
1Istituto Policattedra di Patologia, Università degli Studi di Ancona.
La Clinica Terapeutica
|February 1, 1993
Summary
Raynaud's phenomenon management focuses on symptom relief and trigger avoidance. Medications like calcium-channel blockers and ketanserin can reduce vasospastic attacks, with prostanoids and surgery reserved for severe cases.
Area of Science:
- Vascular Medicine
- Pharmacology
Context:
- Raynaud's phenomenon presents as vasospastic attacks triggered by various factors.
- Current management strategies are primarily symptomatic.
Purpose:
- To review current therapeutic approaches for Raynaud's phenomenon.
- To evaluate the efficacy of different pharmacological agents and interventions.
Summary:
- Hygienic-behavioral measures are crucial for trigger avoidance (cold, smoking, drugs, trauma).
- Nifedipine and newer calcium-channel blockers demonstrate vasodilatory, antiplatelet, and antithrombotic effects, reducing attack frequency and duration.
- Ketanserin offers an alternative, while prostanoids and surgery are reserved for severe, complicated cases.
Impact:
- Provides an overview of evidence-based treatments for Raynaud's phenomenon.
- Highlights the role of vasodilators and alternative agents in managing vasospastic attacks.
- Informs clinical decision-making for optimizing patient care and outcomes.